Market Cap 13.97B
Revenue (ttm) 3.12B
Net Income (ttm) 1.14B
EPS (ttm) N/A
PE Ratio 15.59
Forward PE 13.76
Profit Margin 36.44%
Debt to Equity Ratio 0.00
Volume 1,204,400
Avg Vol 1,306,164
Day's Range N/A - N/A
Shares Out 641.54M
Stochastic %K 20%
Beta 0.95
Analysts Sell
Price Target $30.36

Company Profile

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/...

Industry: Biotechnology
Sector: Healthcare
Phone: 45 70 20 27 28
Address:
Carl Jacobsens Vej 30, Valby, Copenhagen, Denmark
SparkyReturns
SparkyReturns Jul. 31 at 2:43 PM
$TEVA Thought you might like to see. $INCY $GMAB $RDY $NBIX
0 · Reply
SheriffGrover
SheriffGrover Jul. 27 at 2:07 PM
$GMAB https://ugebrev.dk/formue/genmab-transcript-special-call-ser-rina-s-i-markedet-i-2027-med-peak-salg-paa-2-mia-usd/
0 · Reply
Optionking828
Optionking828 Jul. 25 at 1:27 PM
$ABBV $GMAB $JANX $JNJ $RHHBY still won’t matter - Janux is controlled by dark pool
0 · Reply
Quantumup
Quantumup Jul. 25 at 12:07 PM
Cantor reiterated $JANX Overweight-$200 and said, " $JANX unveiled 3 new early-stage pipeline programs after the close." $JNJ $RHHBY $ABBV $GMAB VIR CNTX MRK LVTX Cantor added, "In the context of the validation of its masked TCE platform from strong clinical data for JANX007 (PSMA x CD3 TCE), each of the programs resonates with us. They showcase both the versatility/modularity of the company's platform, as well as the company's creative ability to solve difficult biology challenges. Why now? Investor focus is obviously squarely on '007 so that these updates likely won't move the valuation needle much - but the company had committed to this R&D update at the start of the year. The company was emphatic that this pipeline update is coming from strength and confidence in '007 - and not meant to divert attention from it. With clinical trials expected to get underway over the next 1-4 quarters, this was seen as a prudent time to profile them."
0 · Reply
RaymondR3ddington
RaymondR3ddington Jul. 24 at 4:42 PM
$GMAB 👀
0 · Reply
CDMO
CDMO Jul. 16 at 7:40 PM
$GMAB 💤💤💤
0 · Reply
Pika_Capital
Pika_Capital Jul. 16 at 12:36 PM
$GMAB they won't hold pps forever here. May even add after seeing darzalex sales
0 · Reply
SheriffGrover
SheriffGrover Jul. 16 at 10:53 AM
$GMAB https://ir.genmab.com/news-releases/news-release-details/genmab-announces-net-sales-darzalexr-daratumumab-second-5
0 · Reply
Todd25
Todd25 Jul. 15 at 8:22 PM
$GMAB curious to see JNJ's Darzalex sales tomorrow before the bell, if they beat, I assume GMAB climbs!
1 · Reply
JBurckhardt
JBurckhardt Jul. 11 at 12:01 AM
$GMAB "On June 15, Genmab A/S (NASDAQ:GMAB) announced results from its EPCORE NHL-2 trial, Arm 10. The study tested Epcoritamab, which is a bispecific antibody, in combination with R-ICE chemotherapy. The study was focused on adult patients with relapsed or refractory diffuse large B-cell lymphoma who could undergo autologous stem cell transplantation. The results revealed that the combination therapy achieved an overall response rate of 87%. Moreover, 65% of patients had a complete response where no signs of cancer remained. On the other hand, 23% had a partial response."
0 · Reply
Latest News on GMAB
Genmab Announces Changes to its Executive Committee

Jul 1, 2025, 8:00 AM EDT - 4 weeks ago

Genmab Announces Changes to its Executive Committee


Completion of Share Buy-back Program

Jun 30, 2025, 9:30 AM EDT - 4 weeks ago

Completion of Share Buy-back Program


Transactions in Connection with Share Buy-back Program

Jun 23, 2025, 8:19 AM EDT - 5 weeks ago

Transactions in Connection with Share Buy-back Program


Genmab Announces Financial Results for the First Quarter of 2024

May 8, 2025, 11:01 AM EDT - 3 months ago

Genmab Announces Financial Results for the First Quarter of 2024


Genmab's Outlook Beyond Darzalex's Patent Cliff

Apr 15, 2025, 7:36 AM EDT - 3 months ago

Genmab's Outlook Beyond Darzalex's Patent Cliff


Genmab A/S Share Capital Reduction

Apr 10, 2025, 12:20 PM EDT - 4 months ago

Genmab A/S Share Capital Reduction


Transactions In Connection with Share Buy-back Program

Apr 7, 2025, 7:43 AM EDT - 4 months ago

Transactions In Connection with Share Buy-back Program


Transactions in connection with share buy-back program

Mar 31, 2025, 8:18 AM EDT - 4 months ago

Transactions in connection with share buy-back program


Genmab Announces Initiation of Share Buy-Back Program

Mar 25, 2025, 5:28 PM EDT - 4 months ago

Genmab Announces Initiation of Share Buy-Back Program


Passing of Genmab A/S' Annual General Meeting

Mar 12, 2025, 10:23 AM EDT - 5 months ago

Passing of Genmab A/S' Annual General Meeting


Genmab A/S (GMAB) Q4 2024 Earnings Conference Call Transcript

Feb 14, 2025, 9:32 AM EST - 6 months ago

Genmab A/S (GMAB) Q4 2024 Earnings Conference Call Transcript


Notice to Convene the Annual General Meeting of Genmab A/S

Feb 13, 2025, 6:00 AM EST - 6 months ago

Notice to Convene the Annual General Meeting of Genmab A/S


Genmab Publishes 2024 Annual Report

Feb 12, 2025, 11:01 AM EST - 6 months ago

Genmab Publishes 2024 Annual Report


Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

Jan 22, 2025, 6:23 AM EST - 6 months ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024


Genmab to Hold 2024 R&D Update and ASH Data Review Meeting

Dec 11, 2024, 8:20 AM EST - 8 months ago

Genmab to Hold 2024 R&D Update and ASH Data Review Meeting


Genmab Is Too Attractive To Ignore

Dec 8, 2024, 8:12 AM EST - 8 months ago

Genmab Is Too Attractive To Ignore


SparkyReturns
SparkyReturns Jul. 31 at 2:43 PM
$TEVA Thought you might like to see. $INCY $GMAB $RDY $NBIX
0 · Reply
SheriffGrover
SheriffGrover Jul. 27 at 2:07 PM
$GMAB https://ugebrev.dk/formue/genmab-transcript-special-call-ser-rina-s-i-markedet-i-2027-med-peak-salg-paa-2-mia-usd/
0 · Reply
Optionking828
Optionking828 Jul. 25 at 1:27 PM
$ABBV $GMAB $JANX $JNJ $RHHBY still won’t matter - Janux is controlled by dark pool
0 · Reply
Quantumup
Quantumup Jul. 25 at 12:07 PM
Cantor reiterated $JANX Overweight-$200 and said, " $JANX unveiled 3 new early-stage pipeline programs after the close." $JNJ $RHHBY $ABBV $GMAB VIR CNTX MRK LVTX Cantor added, "In the context of the validation of its masked TCE platform from strong clinical data for JANX007 (PSMA x CD3 TCE), each of the programs resonates with us. They showcase both the versatility/modularity of the company's platform, as well as the company's creative ability to solve difficult biology challenges. Why now? Investor focus is obviously squarely on '007 so that these updates likely won't move the valuation needle much - but the company had committed to this R&D update at the start of the year. The company was emphatic that this pipeline update is coming from strength and confidence in '007 - and not meant to divert attention from it. With clinical trials expected to get underway over the next 1-4 quarters, this was seen as a prudent time to profile them."
0 · Reply
RaymondR3ddington
RaymondR3ddington Jul. 24 at 4:42 PM
$GMAB 👀
0 · Reply
CDMO
CDMO Jul. 16 at 7:40 PM
$GMAB 💤💤💤
0 · Reply
Pika_Capital
Pika_Capital Jul. 16 at 12:36 PM
$GMAB they won't hold pps forever here. May even add after seeing darzalex sales
0 · Reply
SheriffGrover
SheriffGrover Jul. 16 at 10:53 AM
$GMAB https://ir.genmab.com/news-releases/news-release-details/genmab-announces-net-sales-darzalexr-daratumumab-second-5
0 · Reply
Todd25
Todd25 Jul. 15 at 8:22 PM
$GMAB curious to see JNJ's Darzalex sales tomorrow before the bell, if they beat, I assume GMAB climbs!
1 · Reply
JBurckhardt
JBurckhardt Jul. 11 at 12:01 AM
$GMAB "On June 15, Genmab A/S (NASDAQ:GMAB) announced results from its EPCORE NHL-2 trial, Arm 10. The study tested Epcoritamab, which is a bispecific antibody, in combination with R-ICE chemotherapy. The study was focused on adult patients with relapsed or refractory diffuse large B-cell lymphoma who could undergo autologous stem cell transplantation. The results revealed that the combination therapy achieved an overall response rate of 87%. Moreover, 65% of patients had a complete response where no signs of cancer remained. On the other hand, 23% had a partial response."
0 · Reply
JarvisFlow
JarvisFlow Jul. 8 at 3:59 PM
Truist Securities updates rating for Genmab ( $GMAB ) to Buy, target set at 45 → 46.
1 · Reply
Pika_Capital
Pika_Capital Jul. 8 at 3:07 PM
$GMAB so disgustingly cheap here. Loaded and waited for my double
2 · Reply
SheriffGrover
SheriffGrover Jul. 8 at 10:11 AM
$GMAB https://www.youtube.com/watch?v=JSXmQpDA71M
1 · Reply
SparkyReturns
SparkyReturns Jul. 2 at 2:44 PM
$SMMT So, for an Investing idea. Anyone remember when I gave this tip about ICU a few times in the last week...? Yeah. Just getting started. $INCY $GMAB $EXEL
0 · Reply
roblake29
roblake29 Jun. 23 at 9:05 PM
$GMAB My analysis of Genmab. Interesting company. It gets a strong buy from me: https://seekingalpha.com/article/4796541-genmab-this-is-anything-but-a-value-trap-yet-it-is-currently-priced-as-one
1 · Reply
Sowa5000
Sowa5000 Jun. 23 at 6:51 PM
$GMAB very undervalued here. Buy and hold for next 5 years.
0 · Reply
CH_Expat
CH_Expat Jun. 21 at 5:51 PM
$IDYA $ARWR $SNDX $GMAB are my current holdings in descending order. Watch-Shortlist (buying when cheaper) in urgency order: MLTX, TARS, ARQT, MRUS, APGE
0 · Reply
honestinvt7672
honestinvt7672 Jun. 18 at 6:31 AM
$GMAB Great news... Down $1
0 · Reply
AlertsAndNews
AlertsAndNews Jun. 16 at 12:46 AM
$GMAB Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT) In the EPCORE® NHL-2 trial, epcoritamab combined with R-ICE chemoimmunotherapy achieved an 87% overall response rate and 65% complete response rate in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
0 · Reply
DonCorleone77
DonCorleone77 Jun. 16 at 12:39 AM
$GMAB Genmab announces new results fom Phase 1b/2 EPCORE NHL-2 trial Genmab announced new results from the Phase 1b/2 EPCORE NHL-2 trial Arm 10, evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab, ifosfamide, carboplatin, and etoposide, R-ICE, in adult patients with relapsed/refractory diffuse large B-cell lymphoma, R/R DLBCL, who are eligible for autologous stem cell transplantation, ASCT. Results demonstrated an overall response rate, ORR, of 87 percent, a complete response rate of 65 percent and a partial response of 23 percent. The majority of patients proceeded to ASCT. At six months, an estimated 81 percent of responses were ongoing, 74 percent of patients were progression free, and 100 percent of patients were alive. These results were shared today during an oral presentation at the 30th European Hematology Association 2025 Congress. The safety profile of this combination therapy showed cytokine release syndrome being low grade and no discontinuations due to treatment-emergent adverse events. The most common TEAEs were neutropenia, anemia, and thrombocytopenia. CRS occurred in 52 percent; all were low grade and resolved. One patient had immune effector cell-associated neurotoxicity syndrome, which resolved. No clinical tumor lysis syndrome was observed. Infections occurred in 18 patients; five had serious infections. There were no Grade 5 TEAEs.
0 · Reply
Biotekman
Biotekman Jun. 15 at 12:55 PM
$GMAB Wonderful Gem-mab!!!! Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)
1 · Reply
CH_Expat
CH_Expat Jun. 10 at 8:41 AM
$ARWR Avg 15 $IDYA Avg 19 $GMAB Avg 20 $SNDX Avg 11 Was looking for other great value options in bios on the weekend, not finding any better ones. Will add to those four on corrections first before I consider to open new positions.
0 · Reply